STOCK TITAN
  1. Home
  2. News
  3. MIRA

Mira Pharma - MIRA STOCK NEWS

Welcome to our dedicated page for Mira Pharma news (Ticker: MIRA), a resource for investors and traders seeking the latest updates and insights on Mira Pharma stock.

Mira Pharmaceuticals Inc (NASDAQ:MIRA) is a preclinical-stage biopharmaceutical company pioneering novel therapies for neurological and neuropsychiatric disorders. This news hub provides investors and industry stakeholders with timely updates on Ketamir-2 and MIRA-55 development progress, regulatory milestones, and strategic initiatives.

Access authoritative reporting on clinical trial developments, FDA communications, and research breakthroughs related to MIRA's innovative drug candidates. Our curated news collection covers essential updates including:

• Preclinical study results for oral ketamine and marijuana analogs
• Regulatory filings including IND application progress
• Intellectual property developments and partnership announcements
• Scientific presentations at major medical conferences

Bookmark this page for consolidated access to verified MIRA Pharma updates, enabling informed tracking of therapeutic advancements in neuropathic pain management and neurocognitive disorder treatments. Check regularly for new developments in this innovative neuroscience pipeline.

News

MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time

Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (MIRA) will host a shareholder update call on December 5, 2023, to discuss its exclusive licensing agreement for Ketamir-2, a novel oral ketamine analog for depressive disorder treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
conferences
-
News

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (MIRA) revealed groundbreaking insights into the cognitively enhancing effects of MIRA1a in normal mice during a presentation at the University of Louisville. Key findings include the unprecedented cognitive boost of MIRA1a, showcasing its potential in elevating cognitive abilities beyond normal thresholds. Dr. Adam Kaplin's research proposes a revolutionary approach to cognitive impairment treatment, positioning MIRA Pharmaceuticals as a trailblazer in the evolving landscape of psychotropic drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
none
-
News

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced a partnership with MIRALOGX, LLC to develop and commercialize Ketamir-2, a novel oral ketamine analog for refractory depression and depression with suicidal thoughts. Ketamir-2 aims to provide ultra-rapid antidepressant effects and is not classified as a controlled substance by the DEA. Dr. Adam Kaplin, an esteemed expert in ketamine research, will lead the development of Ketamir-2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.06%
Tags
none
News

MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot

Rhea-AI Summary
MIRA Pharmaceuticals presents MIRA1a as a potential alternative to THC with unique properties and fewer side effects at the Cannabinoid Derived Drug Development Summit. Pre-clinical studies show that MIRA1a enhances cognitive performance and diminishes anxiety. The CEO of MIRA Pharmaceuticals highlights the unwanted side effects of marijuana as a reason for seeking alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.8%
Tags
none
-
News

MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts

Rhea-AI Summary
MIRA Pharmaceuticals announces strategic partnership with MZ Group to enhance visibility and potential of drug candidate MIRA1a. MIRA1a has shown therapeutic benefits in treating anxiety, cognitive decline, and neuropathic pain without the side effects of marijuana. The partnership aims to expand MIRA's presence in key markets through investor relations and financial communications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
partnership
-
News

MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit

Rhea-AI Summary
MIRA Pharmaceuticals to present at Cannabinoid-Derived Drug Development Summit, showcasing positive preclinical results on novel synthetic THC analog MIRA1a
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
conferences
News

MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast

Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) is a pre-clinical-stage pharmaceutical development company developing a Novel synthetic THC analog, MIRA1a, to treat anxiety, cognitive decline, and chronic pain. The company recently had its NASDAQ IPO and is working on completing toxicology work in 2024 to apply for a new drug application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
News

MIRA Pharmaceuticals to Ring the Nasdaq Opening Bell on Wednesday, August 9, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
News

MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering

Rhea-AI Summary
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has successfully closed its initial public offering, raising $8.9 million in gross proceeds. The company offered 1,275,000 shares of common stock at an initial public offering price of $7.00 per share. The underwriter has been granted a 45-day option to purchase up to 191,250 additional shares of common stock at the initial public offering price. MIRA's common stock started trading on the Nasdaq Capital Market under the symbol 'MIRA' on August 3, 2023. Kingswood Investments, a division of Kingswood Capital Partners, LLC, acted as the sole bookrunner for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.28%
Tags
IPO offering
News

MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing

Rhea-AI Summary
MIRA Pharmaceuticals, Inc. announces pricing of its IPO at $7.00 per share, expecting to raise $8.9 million. The shares will be listed on Nasdaq Capital Market under the symbol 'MIRA'. The net proceeds will be used for clinical development programs and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
IPO offering
Stock MIRA logo
Mira Pharma

Nasdaq:MIRA

MIRA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

MIRA Stock Data

17.99M
13.48M
23.68%
6.61%
4.26%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
MIAMI